Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Amgen Inc.

AMGN

NEUTRAL

May 22, 2026

Research Conclusion

AMGN at ~$383/share is a HOLD/ACCUMULATE — large-cap biopharma fairly valued on base fundamentals with a high-value binary option (MariTide obesity). PWFV ~$394/share (+3%); intrinsic range $340-450 (~$390 midpoint). FY2025 non-GAAP EPS $20.28 understates economic earning power due to ~$4.09B/yr Horizon amortization — non-GAAP EPS $22.50 (FY2026E) is the correct valuation anchor. The denosumab biosimilar cliff ($6.2B → $2.5B by FY2028) is the primary headwind, offset by a diversified growth portfolio (Repatha +36%, TEZSPIRE +52%, TEPEZZA/KRYSTEXXA from Horizon). MariTide Phase 3 (MARITIME-1 readout early 2027) is the asymmetric catalyst: +33% in the bull case (25% probability); the stock does not require MariTide to justify holding. HOLD/ACCUMULATE at $383 | ADD below $340 | HOLD to $450 | TRIM above $520.

Company Overview & Moat Assessment

Amgen Inc. is one of the world's largest biotechnology companies (~$165B market cap; $36.8B FY2025 revenue), focused on treatments for serious illnesses including cardiovascular disease, oncology, inflammation, bone health, and rare diseases. Core products: Repatha (PCSK9 inhibitor; ~$3.5B, +36% YoY), TEZSPIRE (severe asthma; ~$0.9B, +52%), BLINCYTO (leukemia; growing +23%), Prolia/XGEVA (denosumab; ~$6.2B but declining into biosimilar headwind), and Enbrel (TNF inhibitor; ~$3.9B, mature/declining). The October 2023 Horizon Therapeutics acquisition ($28B) added rare disease franchises: TEPEZZA ($1.9B; thyroid eye disease), KRYSTEXXA ($1.2B; uncontrolled gout), UPLIZNA, and TAVNEOS. MariTide, an anti-obesity biologic in Phase 3 (MARITIME-1/2), is the primary pipeline catalyst with readout expected early 2027. Dividend growth: 11 consecutive years of increases; $9.96/share annualized (2.6% yield).

▲ Bull Case

  • ◆MariTide MARITIME-1 positive — obesity market entry by FY2028: Phase 3 confirms ≥18% weight loss at 12 months; Amgen launches a once-monthly or once-quarterly injectable competing directly with weekly Ozempic; captures 5-8% of $50B+ market by FY2030; pipeline re-rates from mature biopharma to growth biopharma; non-GAAP P/E expands from 17x to 20-22x; FY2028E EPS $32 × 20x = ~$510-640 (+33-67%)
  • ◆Repatha reaches $5.5-6.0B by FY2028 + cardiovascular prevention market expansion: PCSK9 penetration in high-risk cardiovascular patients is still low (~8-12%); Repatha + IRA exclusion + primary prevention label expansion drives volume growth even with pricing headwind; Repatha alone adds $2B revenue from FY2025 base; partially offsets denosumab loss entirely
  • ◆Denosumab cliff less severe than feared + IRA impact contained: Prolia's self-administered, patient-sticky profile slows biosimilar penetration to -10-15%/yr (vs. base -20%); combined with Repatha/TEZSPIRE beat, FY2028 EPS reaches $30+ even without MariTide; at 18x = $540 — bull case achievable without obesity

▼ Bear Case

  • ◆Denosumab cliff -30-35%/yr + IRA hits Repatha and Enbrel: Aggressive biosimilar formulary exclusions accelerate Prolia/XGEVA erosion; concurrent IRA negotiation reduces Repatha by 15% and Enbrel by 20%; combined $2B revenue headwind by FY2028; non-GAAP EPS stuck at $20-21 despite growth portfolio; at 15x = ~$290-315 (-18-24%)
  • ◆MariTide Phase 3 negative — binary event: MARITIME-1 fails to show non-inferiority to Wegovy/Ozempic on weight loss or has unacceptable cardiovascular safety signals; stock drops $40-80 at announcement ($303-343 range); obesity franchise abandoned; pipeline narrative collapses; multiple compressed to 14-15x; FY2028 base case EPS at 15x = $397 (eventually recovers, but 12-18 month overhang)
  • ◆Oral GLP-1 competition preemptively kills MariTide's addressable market: Eli Lilly and Pfizer oral GLP-1 pills achieve >15% weight loss with good tolerability; subcutaneous injectables like MariTide face patient and prescriber preference for oral forms; even a successful Phase 3 doesn't translate to market share; AMGN never builds meaningful obesity revenue; stock trades at 15-16x on mature pharma multiple = $375-400 (no growth premium)
Primary Debate on Wall Street

“The central debate is whether AMGN is a mature-but-stable dividend compounder (17x P/E ceiling) or if MariTide is a legitimate option to transform it into a growth-pharma stock (20-22x P/E). Bull side argues MariTide showed up to 20% weight loss in Phase 2 with once-monthly dosing strongly differentiated vs. weekly Ozempic, and that Amgen's CHO cell-line manufacturing expertise provides competitive advantage. Bear side counters that LLY/NVO have $50B+ combined obesity revenue and are not standing still, with Phase 3 enrollment and comparative efficacy as unknowns, plus Amgen lacks commercial infrastructure in mass-market primary care. Consensus reflects caution on denosumab, modest MariTide probability weighting, and IRA headline risk (10 Buy / 15 Hold / 3 Sell; median PT ~$345-350, 9% below current). Sell-side is underweighting MariTide option value.”

Top Catalysts
  • ◆Q2/Q3 FY2026 denosumab erosion data — Prolia decline ≤-15%/yr pass vs. >-30%/yr fail; cliff absorption tracking
  • ◆Repatha crossing $1.0B/quarter — $1.0B+ confirms $4B+ run-rate vs. <$850M shows deceleration
  • ◆IRA Medicare negotiation list mid-2026 — Repatha/Enbrel excluded or modest reduction vs. >15% Repatha cut
  • ◆MARITIME-1 Phase 3 primary readout early 2027 — ≥18% weight loss & non-inferior vs. inferior data/safety signal
  • ◆FY2027 revenue guidance Aug 2026 — $40B+ confirms cliff absorption vs. <$37B shows cliff winning
  • ◆Net debt milestone <$30B FY2028 — confirms capital allocation optionality vs. >$32B signals FCF constraint
  • ◆Oral GLP-1 competitor Phase 3 readout 2026-2027 — inferior/GI-limited clears MariTide field vs. excellent efficacy collapses market
Top Risks
  • ◆MariTide Phase 3 failure (35-40% probability) — stock drops $40-80 at announcement; recovers to base case over 12-18 months
  • ◆Denosumab faster biosimilar erosion -30%/yr (20-25% probability) — EPS -$2-3 in FY2028 vs base; primary earnings headwind
  • ◆IRA negotiation hits Repatha + Enbrel severely (20-25% probability) — EPS -$1.5-2.0 from FY2027; manageable but constrains upside
  • ◆Oral GLP-1 success caps MariTide market (25-30% probability) — MariTide option value → zero; reduces upside but doesn't affect base case
  • ◆Horizon integration costs exceed plan (10-15% probability) — -$200-400M NI impact; non-GAAP is the right metric

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/AMGN/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.